Max’s operating metrics are superior chiefly due to its hospitals being concentrated in the Delhi NCR region and focus on higher margin-yielding specialities
Utilisation levels in January 2024 surpassed 2023 highs indicating demand uptick
The proposed combined entity is likely to emerge as a pan-India fertiliser company.
The company will have to scale up its top line manifold to be able to protect its profitability
The company’s domestic business continues to grow at a faster pace than the India pharmaceutical market
The business is expected to normalise only from July-September (Q2 FY25) onwards
Rural recovery looks imminent on the back of higher government spending and lower inflation
Some much needed initiatives announced by the government for the agriculture sector
Sun Pharma’s specialty drugs business continue to grow at a brisk pace, helped by ramp-up of key products
An uptick in the RoA will be gradual as the bank continues to invest for the future
The research division proves to be a drag while manufacturing turns out to be the saviour
Scope for near-term RoA expansion looks limited though long-term story intact
The government managed to increase the capital outlay on defence services despite a rapid rise in defence pensions.
The bulk of the TPA’s revenue is linked to the premium under management of health insurers
Order bookings impart improved visibility for FY25 and earnings growth expected to be in mid-teens
Budget 2024: Revenues from passenger services exceeded pre-COVID levels despite a gradual recovery in rail passenger volumes
Earnings growth to be in mid-teens and there is headroom for margin improvement
While this will be an Interim Budget, the overall mood is that the government will continue to spend, particularly because private capex is at a nascent stage and there is buoyancy in government revenues
Despite the rise in late 2023, raw material prices are notably lower than the 2022 highs
Budget 2024: After falling to miniscule levels in 2018-2020, peak power deficit rose to an eight-year high in 2022-2023
Vijaya Diagnostic Centre’s latest acquisition follows similar moves by Dr Lal PathLabs and Metropolis Healthcare
Both Suzlon and Inox Wind reported large order wins in December 2023
There are near-term tailwinds for the gold loan business, while non-gold is doing the heavy-lifting
CESC is the least valued stock among the large electric utilities
The prime driver of growth is the volume visibility from contract duration, which is typically in the range of 2-5 years